SY1 Stock Analysis: Symrise | XETRA
Specialty Chemicals | XETRA, Germany | Market Cap: 12.770m EUR | 12M Return: -2% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 32.2M
EPS Trend: -5.3%
Rev. Trend: 0.7%
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Symrise AG is a German specialty chemicals company founded in 1874 and headquartered in Holzminden, that supplies fragrances, flavorings, cosmetic base materials, active ingredients, and functional ingredients to manufacturers worldwide. The company operates through two main segments: Taste, Nutrition & Health, which provides ingredients and product solutions for food, beverages, pet food, fish feed, and dietary supplements; and Scent & Care, which develops and sells fragrance ingredients, aroma molecules, cosmetic ingredients, and mint flavors for use in perfumes, personal care, cleaning, and oral care products. Symrise serves customers across Europe, Africa, the Middle East, North America, Asia Pacific, and Latin America.
As a specialty chemicals business within the Materials sector, Symrise operates on a B2B (business-to-business) model, selling formulated ingredients and compounds to consumer goods manufacturers rather than directly to end consumers. Companies in this sub-industry typically derive competitive advantage from proprietary formulation capabilities, regulatory expertise, and long-standing customer relationships with global consumer brands in food, beverage, personal care, and household products.
- M&A integration of Diana drives pet food segment margin expansion
- Scent Care pricing tested amid Givaudan and DSM-Firmenich competition
- Emerging markets FX volatility pressures reported revenue growth
| Net Income: 368.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.12 > 0.02 and ΔFCF/TA 4.37 > 1.0 |
| NWC/Revenue: 32.49% < 20% (prev 23.91%; Δ 8.58% < -1%) |
| CFO/TA 0.17 > 3% & CFO 1.38b > Net Income 368.7m |
| Net Debt (1.77b) to EBITDA (1.13b): 1.57 < 3 |
| Current Ratio: 2.52 > 1.5 & < 3 |
| Outstanding Shares: last quarter (136.1m) vs 12m ago -2.53% < -2% |
| Gross Margin: 37.93% > 18% (prev 38.38%; Δ -0.46% > 0.5%) |
| Asset Turnover: 74.81% > 50% (prev 59.34%; Δ 15.47% > 0%) |
| Interest Coverage Ratio: 5.26 > 6 (EBIT TTM 765.9m / Interest Expense TTM 145.6m) |
| A: 0.25 (Total Current Assets 3.31b - Total Current Liabilities 1.31b) / Total Assets 8.11b |
| B: 0.24 (Retained Earnings 1.93b / Total Assets 8.11b) |
| C: 0.09 (EBIT TTM 765.9m / Avg Total Assets 8.21b) |
| D: 0.85 (Book Value of Equity 3.72b / Total Liabilities 4.36b) |
| Altman-Z'' = 3.91 = AA |
| DSRI: 0.84 (Receivables 1.11b/1.06b, Revenue 6.15b/4.94b) |
| GMI: 1.01 (GM 38.38% / 37.93%) |
| AQI: 0.96 (AQ_t 0.40 / AQ_t-1 0.42) |
| SGI: 1.24 (Revenue 6.15b / 4.94b) |
| TATA: -0.12 (NI 368.7m - CFO 1.38b) / TA 8.11b) |
| Beneish M = -3.01 (Cap -4..+1) = AA |
As of July 09, 2026, the stock is trading at EUR 87.64 with a total of 473,829 shares traded. Over the past week, the price has changed by -2.17%, over one month by +15.65%, over three months by +21.10% and over the past year by -2.02%.
Current recommended Stop Loss: 85.10 (which is 2.9% or 1.3 ATR below the current price).
Symrise has no consensus analysts rating.
P/E Trailing = 51.3258
P/E Forward = 22.5734
P/S = 2.5906
P/B = 3.3661
P/EG = 3.3282
Revenue TTM = 6.15b EUR
EBIT TTM = 765.9m EUR
EBITDA TTM = 1.13b EUR
Long Term Debt = 2.06b EUR (from longTermDebt, last quarter)
Short Term Debt = 434.8m EUR (from shortTermDebt, last quarter)
Debt = 2.78b EUR (from shortLongTermDebtTotal, last quarter) + Leases 168.4m
Net Debt = 1.77b EUR (calculated: Debt 2.78b - CCE 1.01b)
Enterprise Value = 14.5b EUR (12.8b + Debt 2.78b - CCE 1.01b)
Interest Coverage Ratio = 5.26 (Ebit TTM 765.9m / Interest Expense TTM 145.6m)
EV/FCF = 14.48x (Enterprise Value 14.5b / FCF TTM 1.00b)
FCF Yield = 6.91% (FCF TTM 1.00b / Enterprise Value 14.5b)
FCF Margin = 16.34% (FCF TTM 1.00b / Revenue TTM 6.15b)
Net Margin = 6.00% (Net Income TTM 368.7m / Revenue TTM 6.15b)
Gross Margin = 37.93% ((Revenue TTM 6.15b - Cost of Revenue TTM 3.82b) / Revenue TTM)
Gross Margin QoQ = 33.57% (prev 41.49%)
Tobins Q-Ratio = 1.79 (Enterprise Value 14.5b / Total Assets 8.11b)
Interest Expense / Debt = 5.23% (Interest Expense 145.6m / Debt 2.78b)
Taxrate = 33.52% (187.4m / 559.2m)
NOPAT = 509.1m (EBIT 765.9m * (1 - 33.52%))
Current Ratio = 2.52 (Total Current Assets 3.31b / Total Current Liabilities 1.31b)
Debt / Equity = 0.75 (Debt 2.78b / totalStockholderEquity, last quarter 3.72b)
Debt / EBITDA = 1.57 (Net Debt 1.77b / EBITDA 1.13b)
Debt / FCF = 1.76 (Net Debt 1.77b / FCF TTM 1.00b)
Total Stockholder Equity = 3.78b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.49% (Net Income 368.7m / Total Assets 8.11b)
RoE = 9.75% (Net Income TTM 368.7m / Total Stockholder Equity 3.78b)
RoCE = 13.11% (EBIT 765.9m / Capital Employed (Equity 3.78b + L.T.Debt 2.06b))
RoIC = 7.36% (NOPAT 509.1m / Invested Capital 6.92b)
WACC = 5.18% (E(12.8b)/V(15.6b) * Re(5.55%) + D(2.78b)/V(15.6b) * Rd(5.23%) * (1-Tc(0.34)))
Discount Rate = 5.55% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -18.40 | Cagr: -1.24%
[DCF] Terminal Value 77.97% ; FCFF base≈869.6m ; Y1≈996.8m ; Y5≈1.47b
[DCF] Fair Price = 145.3 (EV 22.1b - Net Debt 1.77b = Equity 20.3b / Shares 139.8m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: -5.33 | EPS CAGR: -2.06% | SUE: N/A | # QB: 0
Revenue Correlation: 0.74 | Revenue CAGR: 0.07% | SUE: -0.01 | # QB: 0
EPS current Quarter (2026-03-31): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS current Year (2026-12-31): EPS=3.93 | Chg30d=+0.10% | Revisions=+17% | GrowthEPS=+7.1% | GrowthRev=+1.5%
EPS next Year (2027-12-31): EPS=4.26 | Chg30d=+0.29% | Revisions=+15% | GrowthEPS=+8.4% | GrowthRev=+5.1%
[Analyst] Revisions Ratio: +19% (up=8, down=5)